• Explore /
  • Poster
  • / ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.

ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.

Abstract Poster

Authors

Christian Marth

Christian Marth

Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria

Christian Marth , Christof Vulsteke , Maria Jesus Rubio Pérez , Vicky Makker , Elena Ioana Braicu , Iain A. McNeish , Radoslaw Madry , Ali Ayhan , Kosei Hasegawa , Xiaohua Wu , Lea Dutta , Cindy Xu , Stephen Michael Keefe , John J. Lee , Sandro Pignata

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Clinical Trial Registration Number

NCT03884101

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS6106)

DOI

10.1200/JCO.2020.38.15_suppl.TPS6106

Abstract #

TPS6106

Poster Bd #

277

Abstract Disclosures

Similar Posters

First Author: Mario Javier Pineda

First Author: Nicoletta Colombo

First Author: Florence Joly

First Author: Brian M. Slomovitz